goat anti human cd138 syndecan 1  (R&D Systems)

Journal: Frontiers in Immunology

Article Title: Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis

doi: 10.3389/fimmu.2023.1172892

Figure Lengend Snippet: Syndecan-1 (SDC1) is a prognosis biomarker of children with septic shock. (A) ELISA to detect the levels of SDC1and IL-6 in plasma from 28 children with sepsis within 24 hours of PICU admission (day 1). (B) Correlation between levels of IL-6 and SDC1. (C) Changes of levels of SDC1 and heparan sulfate in plasma from day 1 to day 3. (D) ROC curve analysis of SDC1 expression on day 1 between survival group and non-survival group. Bars and error bars represent the mean ± SEM; * p < 0.05, ** p < 0.01.

Article Snippet: Both were incubated with goat anti-mouse primary antibody to SDC1 (1:100; af3190, R&D Systems).

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Expressing

Journal: Frontiers in Immunology

Article Title: Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis

doi: 10.3389/fimmu.2023.1172892

Figure Lengend Snippet: Sulodexide decreased heparinase III-induced shedding of SDC1 in MLMECs. (A) MLMECs were treated with 15 mU/mL Hep III for 2 h, 4 h, or 8 h. Cells in Hep III+SDX group were treated with 30 LSU/mL sulodexide for 2 h before. Cells in the SDX group were treated with sulodexide for 2 h, and then with PBS in the same volume. Representative image of immunofluorescence of SDC1 on MLMECs, scale bar = 200 μm. (B) Densitometry of immunofluorescence of SDC1 on MLMECs. (C) ELISA to detect the levels of SDC1 in MLMECs supernatant with treatment of Hep III for 2 h. Data were expressed as the means ± SEM; * p < 0.05.

Article Snippet: Both were incubated with goat anti-mouse primary antibody to SDC1 (1:100; af3190, R&D Systems).

Techniques: Immunofluorescence, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Immunology

Article Title: Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis

doi: 10.3389/fimmu.2023.1172892

Figure Lengend Snippet: Inhibition of SDC1 shedding by Sulodexide improved lung injury and survival in septic mice. (A) Pattern diagram of the septic mouse model. Mice were pretreated with sulodexide (40 mg/kg) for 2 h before LPS injection or CLP procedure and those mice were observed for 12 h following LPS and 24 h following CLP before euthanasia. (B, D) ELISA to detect the plasma levels of SDC1 and IL-6 in the LPS (20 mg/kg)-challenged (B) and CLP-induced (D) septic model. (C, E) Survival curves after sulodexide administration to LPS (30 mg/kg)-challenged (C) and CLP-induced (E) mice, n=10/group/experiment. (F) Representative lung tissue sections stained with HE at ×100 (D) in LPS-induced sepsis model. (G) Lung tissue W/D weight ratio in LPS- induced sepsis model. (H) Representative immunofluorescence images of SDC1 in lungs, scale bar = 200 μm. (I) Densitometry of SDC1 immunofluorescence in lungs. Data are expressed as means ± SEM; * p < 0.05.

Article Snippet: Both were incubated with goat anti-mouse primary antibody to SDC1 (1:100; af3190, R&D Systems).

Techniques: Inhibition, Injection, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Staining, Immunofluorescence